A Phase III, Multicenter, Randomized, Double-blind, Parallel Group, Active Treatment-controlled Study Assessing the Safety and Efficacy of G238 Compared to Clotrimazole 1% Otic Solution in Patients With Otomycosis
Phase of Trial: Phase III
Latest Information Update: 07 Apr 2017
Price : $35 *
At a glance
- Drugs G 238 (Primary) ; Clotrimazole
- Indications Mycoses
- Focus Registrational; Therapeutic Use
- Sponsors SALVAT
- 15 Apr 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 02 Sep 2014 Planned End Date changed from 1 Apr 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov record.
- 02 Sep 2014 Planned primary completion date changed from 1 Apr 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov record.